Report cover image

Pulmonary Arterial Hypertension (PAH) Medicine Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 119 Pages
SKU # APRC20351761

Description

Summary

According to APO Research, the global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Pulmonary Arterial Hypertension (PAH) Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Pulmonary Arterial Hypertension (PAH) Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Pulmonary Arterial Hypertension (PAH) Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine include Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, Pfizer and Eli Lilly, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH) Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Arterial Hypertension (PAH) Medicine.

The report will help the Pulmonary Arterial Hypertension (PAH) Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Pulmonary Arterial Hypertension (PAH) Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Arterial Hypertension (PAH) Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Company

Actelion Pharmaceuticals
Gilead Sciences
United Therapeutics Corporation
Pfizer
Eli Lilly
Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type

Calcium Channel Blockers
Novel Targeted Drugs
Other
Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application

Secondary Pulmonary Hypertension (SPH)
Primary Pulmonary Hypertension (PPH)
Pulmonary Arterial Hypertension (PAH) Medicine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pulmonary Arterial Hypertension (PAH) Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pulmonary Arterial Hypertension (PAH) Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

119 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (2020-2031)
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2020-2031)
2.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Average Price (2020-2031)
2.3 Pulmonary Arterial Hypertension (PAH) Medicine by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Calcium Channel Blockers
2.3.3 Novel Targeted Drugs
2.3.4 Other
2.4 Pulmonary Arterial Hypertension (PAH) Medicine by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Secondary Pulmonary Hypertension (SPH)
2.4.3 Primary Pulmonary Hypertension (PPH)
3 Market Competitive Landscape by Manufacturers
3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue of Manufacturers (2020-2025)
3.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price by Manufacturers (2020-2025)
3.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Product Type & Application
3.8 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Established Date
3.9 Global Pulmonary Arterial Hypertension (PAH) Medicine Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Actelion Pharmaceuticals
4.1.1 Actelion Pharmaceuticals Company Information
4.1.2 Actelion Pharmaceuticals Business Overview
4.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
4.1.5 Actelion Pharmaceuticals Recent Developments
4.2 Gilead Sciences
4.2.1 Gilead Sciences Company Information
4.2.2 Gilead Sciences Business Overview
4.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
4.2.5 Gilead Sciences Recent Developments
4.3 United Therapeutics Corporation
4.3.1 United Therapeutics Corporation Company Information
4.3.2 United Therapeutics Corporation Business Overview
4.3.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2020-2025)
4.3.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
4.3.5 United Therapeutics Corporation Recent Developments
4.4 Pfizer
4.4.1 Pfizer Company Information
4.4.2 Pfizer Business Overview
4.4.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
4.4.5 Pfizer Recent Developments
4.5 Eli Lilly
4.5.1 Eli Lilly Company Information
4.5.2 Eli Lilly Business Overview
4.5.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
4.5.5 Eli Lilly Recent Developments
5 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Scenario by Region
5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2020-2031
5.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2020-2025
5.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2026-2031
5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2020-2031
5.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2020-2025
5.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2026-2031
5.4 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
5.4.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2020-2031)
5.4.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
5.5.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2020-2031)
5.5.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
5.6.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2020-2031)
5.6.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
5.7.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2020-2031)
5.7.3 South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
5.8.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2020-2031)
5.8.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2020-2031)
6.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2020-2031) & (K Units)
6.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2020-2031)
6.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2020-2031)
6.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2020-2031)
6.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2020-2031)
7 Segment by Application
7.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2020-2031)
7.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2020-2031) & (K Units)
7.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2020-2031)
7.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2020-2031)
7.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2020-2031)
7.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Analysis
8.1.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process
8.2 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
8.2.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers
9 Global Pulmonary Arterial Hypertension (PAH) Medicine Analyzing Market Dynamics
9.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
9.2 Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers
9.3 Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges
9.4 Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.